title: Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
abstract: Drugs that target the tumor vasculature and inhibit angiogenesis are widely used for cancer treatment. Individual tumors show large differences in vascularity, but it is uncertain how these differences affect responsiveness to antiangiogenesis. We investigated this question using two closely related prostate cancer models that differ markedly in tumor vascularity: PC3, which has very low vascularity, and the PC3-derived cancer stem-like cell holoclone PC3/2G7, which forms tumors with high microvessel density, high tumor blood flow, and low hypoxia compared with parental PC3 tumors. Three angiogenesis inhibitors (axitinib, sorafenib, and DC101) all induced significantly greater decreases in tumor blood flow and microvessel density in PC3/2G7 tumors compared with PC3 tumors, as well as significantly greater decreases in tumor cell proliferation and cell viability and a greater increase in apoptosis. The increased sensitivity of PC3/2G7 tumors to antiangiogenesis indicates they are less tolerant of low vascularity and suggests they become addicted to their oxygen- and nutrient-rich environment. PC3/2G7 tumors showed strong upregulation of the proangiogenic factors chemokine ligand 2 (CCL2) and VEGFA compared with PC3 tumors, which may contribute to their increased vascularity, and they have significantly lower endothelial cell pericyte coverage, which may contribute to their greater sensitivity to antiangiogenesis. Interestingly, high levels of VEGF receptor-2 were expressed on PC3 but not PC3/2G7 tumor cells, which may contribute to the growth static response of PC3 tumors to VEGF-targeted antiangiogenesis. Finally, prolonged antiangiogenic treatment led to resumption of PC3/2G7 tumor growth and neovascularization, indicating these cancer stem-like cell-derived tumors can adapt and escape from antiangiogenesis.
authors: Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts, USA.
authors: Kexiong
authors: K
authors: Zhang
authors: David J
authors: DJ
authors: Waxman
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D000077784:Axitinib; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D006801:Humans; D000860:Hypoxia; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology; D007191:Indazoles / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D009536:Niacinamide / Q000031:analogs & derivatives / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D000077157:Sorafenib; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007093:Imidazoles; D007191:Indazoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib; D000077784:Axitinib
references: Nat Rev Drug Discov. 2011 Jun;10(6):417-27
references: 21629292
references: Curr Urol Rep. 2008 Jan;9(1):26-33
references: 18366971
references: J Clin Oncol. 2008 Jun 10;26(17):2839-45
references: 18539962
references: J Natl Cancer Inst. 2002 Jun 19;94(12):883-93
references: 12072542
references: Nat Rev Cancer. 2008 Aug;8(8):592-603
references: 18650835
references: Expert Opin Ther Targets. 2013 Jan;17(1):7-20
references: 23121690
references: Nature. 2010 Dec 9;468(7325):829-33
references: 21102433
references: Nature. 2010 Dec 9;468(7325):824-8
references: 21102434
references: BJU Int. 2005 Dec;96(9):1319-22
references: 16287453
references: Cancer Res. 2006 Aug 15;66(16):7843-8
references: 16912155
references: Nature. 1996 Jan 4;379(6560):88-91
references: 8538748
references: Mol Cancer Ther. 2007 Nov;6(11):2879-90
references: 17989319
references: Invest New Drugs. 2012 Aug;30(4):1791-801
references: 21573959
references: Mol Cancer Ther. 2008 Dec;7(12):3670-84
references: 19074844
references: Front Biosci (Landmark Ed). 2009 Jan 01;14:3962-73
references: 19273326
references: Clin Cancer Res. 2008 Nov 15;14(22):7272-83
references: 19010843
references: Crit Rev Oncol Hematol. 2006 Jul;59(1):15-26
references: 16716598
references: Mol Cancer. 2010 Dec 29;9:319
references: 21190562
references: Clin Cancer Res. 1999 Apr;5(4):783-9
references: 10213213
references: Clin Cancer Res. 2002 Aug;8(8):2714-24
references: 12171905
references: Mol Cancer Ther. 2008 Oct;7(10):3129-40
references: 18852116
references: Cancer Cell. 2004 Jan;5(1):13-7
references: 14749122
references: Histopathology. 2005 May;46(5):481-9
references: 15842629
references: Prostate. 1997 Sep 15;33(1):38-45
references: 9294625
references: Br J Cancer. 2002 May 20;86(10):1566-77
references: 12085206
references: Clin Cancer Res. 2009 Jan 15;15(2):578-88
references: 19147763
references: Cancer Res. 2009 Sep 15;69(18):7243-51
references: 19738068
references: Microcirculation. 2012 Feb;19(2):115-25
references: 22078005
references: Int J Dev Biol. 2011;55(3):261-8
references: 21710434
references: Blood. 2001 Sep 15;98(6):1904-13
references: 11535528
references: Cell. 1996 Aug 9;86(3):353-64
references: 8756718
references: Rev Recent Clin Trials. 2008 May;3(2):97-103
references: 18474019
references: Cancer Lett. 2012 Jul 28;320(2):130-7
references: 22425960
references: J Natl Cancer Inst. 2001 Mar 7;93(5):382-7
references: 11238700
references: Mol Cancer Ther. 2008 Jan;7(1):79-89
references: 18202011
references: In Vivo. 2004 Mar-Apr;18(2):155-60
references: 15113042
references: FASEB J. 2007 Dec;21(14):3777-85
references: 17625071
references: Cytokine Growth Factor Rev. 2010 Feb;21(1):41-8
references: 20005149
references: Cancer Res. 2010 Mar 15;70(6):2213-23
references: 20197469
references: Cancer Res. 2004 Sep 15;64(18):6616-25
references: 15374976
references: Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1038-46
references: 14575835
references: Cancer Metastasis Rev. 2007 Dec;26(3-4):443-52
references: 17786538
references: Carcinogenesis. 2006 Sep;27(9):1883-93
references: 16624828
references: Crit Rev Oncog. 2012;17(1):51-67
references: 22471664
references: Neoplasia. 2001 Jan-Feb;3(1):33-42
references: 11326314
references: Mol Oncol. 2011 Apr;5(2):137-49
references: 21345752
references: J Clin Invest. 1999 Jan;103(2):159-65
references: 9916127
references: Cancer Res. 2000 Mar 1;60(5):1388-93
references: 10728704
references: Nature. 2004 Jul 15;430(6997):350-6
references: 15254537
references: Cancer Res. 2006 Apr 1;66(7):3639-48
references: 16585189